...$2.53) -9% -185.9 $1,880.0 EPS excludes a tax gain of $0.15 from the acquisition of Kinetek...

...first quarter GAAP EPS of $0.34, which includes a tax gain from its acquisition of Kinetek...

...Kinetek for an aggregate cash payment of about $2.7 million. In June 2001, QLT and Kinetek...
...kidney diseases. QLT expects the deal to increase 2004 EPS by $0.10 to $0.84- $0.96. Kinetek Pharmaceuticals Inc....

...and principal at Management Associates; and James Hudson, former SVP of finance and CFO at Kinetek Pharmaceuticals Inc....

...cellular delivery technologies to knock-down the expression of signal transduction kinase targets supplied by Kinetek. Kinetek...
...GeneBloc molecules to validate the gene function of the targets. atugen AG , Berlin, Germany Kinetek Pharmaceuticals Inc....

...technologies to knock-down the expression of signal transduction kinase targets supplied by Kinetek (Vancover, B.C.). Kinetek...

...treating either alopecia or benign prostatic hyperplasia. Earlier this year, QLTI signed a deal with Kinetek Pharmaceuticals Inc....

...QLT and Kinetek will develop signal transduction inhibitors to treat ophthalmic, immune system and kidney diseases...
...to treat ophthalmic, immune system and kidney diseases. QLT invested C$11 million (US$7.2 million) in Kinetek...
...initial equity investment, Kinetek will receive a C$5.5 million investment from certain existing Kinetek shareholders. Kinetek Pharmaceuticals Inc....

...QLT (TSE:QLT; QLTI) and Kinetek (Vancouver, B.C.) will develop signal transduction inhibitors to treat ophthalmic, immune...
...to treat ophthalmic, immune system and kidney diseases. QLT invested C$11 million (US$7.2 million) in Kinetek...
...with QLT's initial equity investment, Kinetek will receive a C$5 million investment from certain existing Kinetek...